PharmaCyte Biotech
PMCB
PMCB
29 hedge funds and large institutions have $2.32M invested in PharmaCyte Biotech in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
29
Holders Change
-3
Holders Change %
-9.38%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
10
Closed
4
Calls
$63K
Puts
$1K
Net Calls
+$62K
Net Calls Change
+$57K
Top Buyers
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$54.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$45.4K |
| 3 |
Renaissance Technologies
New York
|
+$13.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.74K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.21K |
Top Sellers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$178K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$47.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$36.4K |
| 4 |
Bank of New York Mellon
New York
|
-$35.9K |
| 5 |
Squarepoint
New York
|
-$32.1K |
